PhaseRx liver disease drug receives boost from FDA, stock soars by Clare McGrane on November 29, 2016November 29, 2016 at 9:34 am Seattle-based biotech company PhaseRx develops drug candidates to treat rare, often life-threatening liver diseases, and one of their candidates just got a boost from the FDA. The company’s leading drug, called… Read More